Literature DB >> 15855830

Voltage-dependent and frequency-independent inhibition of recombinant Cav3.2 T-type Ca2+ channel by bepridil.

Tomoko Uchino1, Tae-Seong Lee, Toshihiko Kaku, Noboru Yamashita, Takayuki Noguchi, Katsushige Ono.   

Abstract

Effects of bepridil on the low voltage-activated T-type Ca2+ channel (CaV3.2) current stably expressed in human embryonic kidney (HEK)-293 cells were examined using patch-clamp techniques. Bepridil potently inhibited ICa,T with a markedly voltage-dependent manner; the IC50 of bepridil was 0.4 micromol/l at the holding potential of -70 mV, which was 26 times as potent as that at -100 mV (10.6 micromol/l). Steady-state inactivation curve (8.4 +/- 1.7 mV) and conductance curve (5.9 +/- 1.9 mV) were shifted to the hyperpolarized potential by 10 micromol/l bepridil. Bepridil exerted the tonic blocking action but not the use-dependent block. Bepridil had no effect on the recovery from inactivation of T-type Ca2+ channels. Thus, high efficacy of bepridil for terminating atrial fibrillation and atrial flutter may be considered to be attributed, at least in a part, to the T-type Ca2+ channel-blocking actions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855830     DOI: 10.1159/000085329

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  7 in total

Review 1.  Development of newer calcium channel antagonists: therapeutic potential of efonidipine in preventing electrical remodelling during atrial fibrillation.

Authors:  Narutaka Ohashi; Hideo Mitamura; Satoshi Ogawa
Journal:  Drugs       Date:  2009       Impact factor: 9.546

2.  Window current through the T-type Ca2+ channel triggers the mechanism for cellular apoptosis via mitochondrial pathways.

Authors:  Tomoko Uchino; Shojiro Isomoto; Takayuki Noguchi; Katsushige Ono
Journal:  Heart Vessels       Date:  2013-01-18       Impact factor: 2.037

3.  Short- and long-term inhibition of cardiac inward-rectifier potassium channel current by an antiarrhythmic drug bepridil.

Authors:  Fangfang Ma; Hiroki Takanari; Kimiko Masuda; Masaki Morishima; Katsushige Ono
Journal:  Heart Vessels       Date:  2015-10-26       Impact factor: 2.037

4.  Bepridil up-regulates cardiac Na+ channels as a long-term effect by blunting proteasome signals through inhibition of calmodulin activity.

Authors:  L Kang; M Q Zheng; M Morishima; Y Wang; T Kaku; K Ono
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

5.  Comparison of the effects of bepridil and aprindine for the prevention of atrial fibrillation after cardiac and aortic surgery: A prospective randomized study.

Authors:  Mahito Ozawa; Takashi Komatsu; Yoshihiro Sato; Fusanori Kunugita; Hideaki Tachibana; Atsushi Tashiro; Hitoshi Okabayashi; Motoyuki Nakamura
Journal:  J Arrhythm       Date:  2015-05-16

Review 6.  Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action.

Authors:  Patrício Soares-da-Silva; Nuno Pires; Maria João Bonifácio; Ana I Loureiro; Nuno Palma; Lyndon C Wright
Journal:  Pharmacol Res Perspect       Date:  2015-03-30

7.  Responsiveness to bepridil predicts atrial substrate in patients with persistent atrial fibrillation.

Authors:  Daisuke Yakabe; Yusuke Fukuyama; Masahiro Araki; Toshihiro Nakamura
Journal:  J Arrhythm       Date:  2021-01-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.